Please login to the form below

Not currently logged in

Glycotope appoints Dr Alfredo Zurlo as chief medical officer

He joins the German clinical-stage immuno-oncology company from Mologen

Glycotope Alfredo ZurloGerman clinical-stage immuno-oncology company Glycotope has appointed Dr Alfredo Zurlo as chief medical officer.

He joins the firm from Mologen AG, where he was its chief medical officer and a member of the Berlin-based biotech's executive board.

Prior that Dr Zurlo held various positions at F Hoffmann La Roche and Roche SA, including senior international medical leader director oncology and medical director oncology.

Previous to his time at Roche he was a medical advisor for the European Organisation for the Research and Treatment of Cancer (EORTC).

Glycotope's chief executive officer Paul Higham said: “We are delighted that Alfredo has decided to join Glycotope. He has an exceptionally strong background in oncology both in a clinical setting and within companies developing and marketing treatments for cancer.

“His experience in designing and managing clinical trials will be invaluable as we continue to advance our mature and growing pipeline of proprietary cancer therapies including our oncology lead PankoMab-GEX which is currently in phase IIb in ovarian cancer.“

11th May 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...